Atezolizumab 1.875g/15ml solution for injection vials
NHS hospitals in England used £89,538,957 of indicative cost of Atezolizumab 1.875g/15ml solution for injection vials in the 12 months to April 2026, about 0.4% of all hospital medicines spend. That is up 38.3% on the previous 12 months.
Indicative cost · 12 months
Quantity (VMP units) · 12 months
Share of hospital medicines spend
Figure 1. Atezolizumab 1.875g/15ml solution for injection vials: NHS hospital indicative cost by month (£ millions)
Source: NHSBSA Secondary Care Medicines Data, to April 2026
Cost is indicative — actual hospital medicine prices are commercially confidential, so these figures are estimated from list prices. See methodology.
NHS trusts using Atezolizumab 1.875g/15ml solution for injection vials most
By indicative cost over the 12 months to April 2026.
| NHS trust | Indicative cost (12 months) |
|---|---|
| The Clatterbridge Cancer Centre Nhs Ft | £15,409,721 |
| The Christie Nhs Foundation Trust | £6,564,458 |
| Royal Surrey County Hosp Nhs Found Trust | £3,328,804 |
| Royal Free London Nhs Foundation Trust | £2,878,614 |
| The Newcastle Upon Tyne Hpl Nhs Found Tr | £2,756,768 |
| Hull And East Yorkshire Hpls Nhs Trust | £2,714,883 |
| James Paget Univ Hospitals Nhs Ft | £2,292,229 |
| Lancashire T/Ing Hsp Nhs Foundation Trus | £1,801,037 |
| Imperial College Healthcare Nhs Trust | £1,793,422 |
| South Tyneside And Sunderland Nhs Ft | £1,732,499 |
The primary-care picture
No confident match to a community-dispensed medicine was found for this product, so no primary-care comparison is shown. SCMD products are recorded at product level, which does not always map cleanly to a BNF substance.